Celebrations may be in order for Caribou Biosciences, Inc.( NASDAQ:CRBU ) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The revenue forecast for this year has experienced a facelift, with analysts now much more optimistic on its sales pipeline. The market seems to be pricing in some improvement in the business too, with the stock up 5.2% over the past week, closing at US$2.03. Could this big upgrade push the stock even higher?
Following the upgrade, the current consensus from Caribou Biosciences' five analysts is for revenues of US$34m in 2026 which - if met - would reflect a huge 199% increase on its sales over the past 12 months. The loss per share is expected to ameliorate slightly, reducing to US$1.24. However, before this estimates update, the consensus had been expecting revenues of US$26m and US$1.33 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
View our latest analysis for Caribou Biosciences
There was no major change to the consensus price target of US$12.00, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Caribou Biosciences' past performance and to peers in the same industry. The analysts are definitely expecting Caribou Biosciences' growth to accelerate, with the forecast 3x annualised growth to the end of 2026 ranking favourably alongside historical growth of 4.7% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 22% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Caribou Biosciences is expected to grow much faster than its industry.
The Bottom Line
The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Caribou Biosciences is moving incrementally towards profitability. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Caribou Biosciences.
Still, the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Caribou Biosciences going out to 2028, and you can see them free on our platform here. .
Of course, seeing company management invest large sums of moneyin a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership .
Have feedback on this article? Concerned about the content? Get in touch
with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature.
We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
